P270 ‘Act on Axial SpA': a gold standard time to diagnosis
Notice bibliographique
Résumé
Abstract Background/Aims A lack of public understanding of the symptoms of axial spondyloathritis (axial SpA) is a significant factor in diagnostic delay. Research commissioned by The National Axial Spondyloarthritis Society (NASS) found that 91% of the UK population had never heard of axial SpA, despite more people living with the condition than MS and Parkinson’s combined. Additionally, 8 in 10 people could not identify the symptoms of axial SpA when prompted. As part of a 5-year programme called ‘Act on Axial SpA’, NASS created the first phase of a campaign to increase public awareness, help people recognise symptoms, and encourage them to visit their GP if concerned. Aims: 1) Ensure people have heard of axial SpA. 2) Help people understand that it’s a condition that affects young people. 3) Ensure people recognise the signs and symptoms of the condition. 4) Get people to visit actonaxialspa.com to use the symptom checker and visit their GP if concerned. Methods 1) Raise awareness about the condition: to make an emotional connection with a cold audience, who are unlikely to have heard of axial SpA (AS) and show them why the campaign is relevant to them. We told stories about people with the condition and their families, so people can see that the condition could affect someone like ‘them’. We ensured our campaign key messages are highly visible in the places, publications and online media people in our target audiences are likely to see every day. 2) Identify a core set of symptoms using a newly developed acronym (SPINE). 3) Direct people to an online symptom checker which combines the ASAS, Berlin and Calin inflammatory back pain criteria. 4) Provide information for the patient and primary care professional on the results of the symptom checker and next steps as per the NICE guidelines 5) Provide information for the patient on preparing for their GP and rheumatologist appointments. Results We report results from June 23 - October 13 2021. 1) Case studies have featured in 11 national media publications with a combined reach of over 101 million. 2) Social media activity has a reach of 440,000. 3) Video content has been viewed 375,000 times. 4) 1,264 people have used the symptom checker. 5) We are reaching new audiences, in particular those aged 18-45 and a larger proportion of women. Conclusion The first phase of the campaign has demonstrated cut through to new audiences. People are interested, engaged and eager to learn more about axial SpA. When people are aware of the condition and its symptoms, they are more likely to act. We are confident that, with time, the ‘Act on Axial SpA’ public awareness campaign will play a huge part in reducing diagnosis times for people with axial SpA. Disclosure L. Marshall: None. D. Webb: None. F. MacAulay: None. K. Gaffney: Consultancies; Novartis, AbbVie, UCB, Lilly, Pfizer. Shareholder/stock ownership; SpA Academy www.spaacademy.org. Honoraria; Novartis, AbbVie, UCB, Lilly, Pfizer. Member of speakers’ bureau; Novartis, UCB, AbbVie, Lilly. Grants/research support; NASS, AbbVie, Pfizer, UCB, Novartis, Lilly, Cellgene, Celltrion, Janssen, Gilead, Biogen. Other; Expenses: Abbvie, Lilly, Roche, Novartis, Pfizer and UCB. R. Sengupta: Consultancies; Abbvie, Biogen, Celgene, Chugai, Lilly, MSD, Novartis, UCB. Honoraria; Abbvie, Biogen, Celgene, Chugai, Lilly, MSD, Novartis, UCB. Grants/research support; Abbvie, Celgene, Novartis, UCB. Other; Advisory boards:, Abbvie, Biogen, Chugai, Lilly, Novartis, UCB.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,012 | 0,041 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,002 |
| Bibliométrie | 0,005 | 0,002 |
| Études des sciences et des technologies | 0,002 | 0,001 |
| Communication savante | 0,003 | 0,004 |
| Science ouverte | 0,003 | 0,004 |
| Intégrité de la recherche | 0,003 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,017 | 0,014 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».